Technology Appraisal Guidance No. 325
Source: National Institute for Health and Care Excellence
1.1 Nalmefene is recommended within its marketing authorisation, as an option for reducing alcohol consumption, for people with alcohol dependence:
- who have a high drinking risk level (defined as alcohol consumption of more than 60 g per day for men and more than 40 g per day for women, according to the ) without physical withdrawal symptoms and
- who do not require immediate detoxification.
The marketing authorisation states that nalmefene should:
- only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption and
- be initiated only in patients who continue to have a high drinking risk level 2 weeks after initial assessment.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:
Nalmefene for reducing alcohol consumption in people with alcohol dependence.
Issue Date: November 2014